Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07190248 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | recruiting | Phase 3 | 675 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Sep 28, 2026 | clinicaltrials |
| NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)(AB02) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 19 | Sep 28, 2026 |
| clinicaltrials |
| NCT07222267 | An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 86 | BeOne MedicinesINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07226349 | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 105 | BeOne MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07226999 | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 550 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | recruiting | Phase 3 | 500 | BeOne MedicinesINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | recruiting | Phase 1 | 260 | IDEAYA BiosciencesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07293754 | An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors(RaPTR-101) | recruiting | Phase 1 / Phase 2 | 150 | Repertoire Immune MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07305428 | Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study | recruiting | N/A | 30 | The University of Hong KongOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | recruiting | Phase 2 | 162 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07346157 | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease(PNOC044) | recruiting | Phase 1 / Phase 2 | 69 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07372079 | Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy | recruiting | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07380646 | the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer | recruiting | Phase 2 | 97 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | recruiting | Phase 3 | 1,978 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07414836 | A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 84 | BeOne MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 132 | PfizerINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07432178 | CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon) | recruiting | Phase 3 | 2,288 | Fudan UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07439653 | A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 155 | TORL Biotherapeutics, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07460440 | SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier(SPARC) | recruiting | — | 240 | University of UtahOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07498907 | Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma(LUXUS41) | recruiting | Phase 3 | 192 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07513376 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)(INTerpath-014) | recruiting | Phase 3 | 876 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | recruiting | Phase 1 | 250 | PfizerINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT07553234 | Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment(GEMMA) | recruiting | N/A | 20 | University of ChicagoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 265 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07601334 | Safety and Activity of HF50 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 45 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )(RASolute 305) | recruiting | Phase 3 | 670 | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07660939 | GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders | recruiting | Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07685717 | Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 50 | Jennifer WoyachOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07704476 | EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer | recruiting | N/A | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07722611 | A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) | recruiting | Phase 2 / Phase 3 | 380 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07733024 | Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer(DSC-NEC) | recruiting | Phase 2 | 200 | Tingting YuanOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07733180 | A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC | recruiting | Phase 2 | 30 | BeOne MedicinesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07839247 | Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL | recruiting | Phase 2 | 33 | Xiaohui RenOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844473 | Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer(MagBracket) | recruiting | N/A | 35 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844941 | Artificial Intelligence (AI)-Based Personalized Exercise Coaching for Patients With Breast Cancer | recruiting | N/A | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07845422 | A Study of Music Therapy for Anxiety in People With Cancer | recruiting | N/A | 240 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT02945579 | Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | recruiting | N/A | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03342144 | Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting(VeRVe) | recruiting | — | 500 | AbbVieINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT03460977 | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | recruiting | Phase 1 | 453 | PfizerINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | recruiting | Phase 1 / Phase 2 | 890 | Regeneron PharmaceuticalsINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT03629171 | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | recruiting | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03702309 | Liquid Biopsy Evaluation and Repository Development at Princess Margaret(LIBERATE) | recruiting | — | 2,500 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03741426 | WIRE - Novel Treatments in Renal Cell Cancer(WIRE) | recruiting | Phase 2 | 134 | CCTU- Cancer ThemeOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03896568 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04094610 | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | recruiting | Phase 1 / Phase 2 | 75 | Turning Point Therapeutics, Inc.INDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials